Stifel Maintains Buy on Spyre Therapeutics, Raises Price Target to $27
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Alex Thompson has reaffirmed a Buy rating on Spyre Therapeutics (NASDAQ:SYRE) and increased the price target from $23 to $27.
December 18, 2023 | 3:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Alex Thompson maintains a Buy rating on Spyre Therapeutics and raises the price target to $27.
The increase in price target by a reputable analyst typically signals a positive outlook on the company's future performance, which can lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100